Home/Supernus Pharmaceuticals/Kevin T. Anderson, Esq.

KT

Kevin T. Anderson, Esq.

Compliance Officer

Supernus Pharmaceuticals

Therapeutic Areas

Neurology Psychiatry

Supernus Pharmaceuticals Pipeline

Drug	Indication	Phase
SPN-820/821	Treatment-Resistant Depression	Phase 3
SPN-817	Severe Epilepsy	Phase 2
ZURZUVAE (zuranolone)	Postpartum Depression	Approved
QELBREE (viloxazine ER)	ADHD	Approved

Leadership Team at Supernus Pharmaceuticals

Jack A. Khattar

President and Chief Executive Officer, Director

Senior Vice President, Chief Financial Officer

View full Supernus Pharmaceuticals profile